Pulmatrix Gross Profit 2014-2021 | PULM

Pulmatrix gross profit from 2014 to 2021. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Pulmatrix Annual Gross Profit
(Millions of US $)
2020 $13
2019 $8
2018 $0
2017 $0
2016 $1
2015 $1
2014 $0
2014 $
2013 $
2013 $
2012 $
Pulmatrix Quarterly Gross Profit
(Millions of US $)
2021-09-30 $1
2021-06-30 $2
2021-03-31 $1
2020-12-31 $2
2020-09-30 $4
2020-06-30 $4
2020-03-31 $3
2019-12-31 $2
2019-09-30 $1
2019-06-30 $5
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31 $0
2017-12-31
2017-09-30 $0
2017-06-30
2017-03-31
2016-12-31 $0
2016-09-30 $0
2016-06-30 $0
2016-03-31 $0
2015-12-31 $0
2015-09-30 $1
2015-06-30 $0
2015-03-31 $0
2014-12-31
2014-09-30 $0
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.023B $0.013B
Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage. Its technology platform consists of iSPERSE. Pulmatrix, Inc., formerly known as Ruthigen, Inc., is based in Lexington, MA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.345B 9.06
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.301B 19.14
Biohaven Pharmaceutical Holding (BHVN) United States $7.598B 0.00
Emergent Biosolutions (EBS) United States $2.503B 9.00
Arcus Biosciences (RCUS) United States $2.274B 0.00
Myovant Sciences (MYOV) United Kingdom $1.296B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.081B 0.00
Zymeworks (ZYME) Canada $0.538B 0.00
SQZ Biotechnologies (SQZ) United States $0.203B 0.00
Ambrx Biopharma (AMAM) United States $0.201B 0.00
Enzo Biochem (ENZ) United States $0.155B 20.00